Developer docs
API playgroundTry for free, no card

Search company profiles

Agility Life Sciences

Full company profile

uuid00qn5g5

Namestring
Agility Life Sciences
Legal namestring
Agility Life Sciences
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Agility Life Sciences is a privately held, founder-led formulation development CDMO founded in 2012 and headquartered in Stapleford, Nottingham, United Kingdom. The company develops drug formulations for small molecules and peptides, addressing bioavailability, solubility, permeability, stability, and targeted delivery challenges (including blood-brain barrier crossing) for pharmaceutical and biotech innovators across routes of administration spanning oral, ocular, intranasal, topical, subcutaneous, and transdermal. Its core technology portfolio covers spray drying, amorphous solid dispersions, lipid nanoparticles, liposomes, and a range of release-profile modification techniques, delivered through a proprietary methodology branded as "Futureproof Formulations Fast™." The firm also provides analytical method development and validation (HPLC and related techniques) and CMC/regulatory consulting, including authoring CMC sections for regulatory documents.

Agility operates a pure fee-for-service, project-based revenue model: all services are billed on a per-project basis, and all intellectual property generated during an engagement is retained by the client. The company goes to market through direct enterprise sales led by its CEO, CSO, and a dedicated business development executive, supported by a heavy conference presence (BOS Basel, ON Helix, ELRIG, NLS, CPHI Milan), thought-leadership content on LinkedIn, and podcast appearances by the CEO. In October 2025, Agility entered an Integrated CMC Partnership with Sai Life Sciences (a large Indian-listed CRDMO) and Centrix Pharma Solutions to offer end-to-end drug substance, formulation, and clinical manufacturing services to innovator biopharma, materially extending its distribution and service scope without organic capex. The firm's customer base spans pharma/biotech innovators as the primary segment and nutraceutical/food supplement companies as a secondary segment. With 11-50 employees and no external funding rounds disclosed, Agility is positioned as a boutique, science-led CDMO.

Short descriptiontext

Agility Life Sciences is a UK-based, founder-led formulation development CDMO that helps pharmaceutical and biotech innovators solve bioavailability, solubility, and delivery challenges for small molecules and peptides across oral, ocular, intranasal, and topical routes via fee-for-service projects.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
formulation development services, contract development CDMO, CMC consulting services, analytical method development, pharmaceutical formulation
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fee-for-service formulation development
TypeProfessional Services
Description

All formulation development services are conducted on a fee-for-service basis. All IP generated during the engagement belongs to the client. This is a project-based, service revenue model targeting preclinical through commercial development stages.

agilitylifesciences.com
2Fee-for-service analytical development
TypeProfessional Services
Description

Analytical method development and validation services provided as standalone projects or alongside formulation projects. Project-based pricing.

agilitylifesciences.com
3CMC consulting
TypeProfessional Services
Description

CMC, analytical and formulation development consulting services, including writing CMC sections for regulatory documents.

agilitylifesciences.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Agility Life Sciences is a CDMO that turns poorly behaved small molecules and peptides into optimized pharmaceutical formulations for preclinical, clinical, and commercial stages. Services include formulation development across oral, ocular, intranasal, and topical routes; solubility and permeability enhancement; lipid nanoparticle and liposomal formulations; release profile modification; analytical method development; and CMC, analytical, and regulatory consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Accelerated molecule progression from preclinical to clinic and commercial
Product overview1 text field

Agility Life Sciences is an award-winning formulation development CDMO operating as a single unified service offering called 'Futureproof Formulations Fast™'. The company transforms 'badly behaved molecules' into smart formulations for small molecules and peptides. The core service portfolio includes solubility enhancement solutions (spray drying, amorphous solid dispersions, lipid nanoparticles, liposomes), permeability enhancement (particularly for CNS/blood-brain barrier delivery), and release profile modification. Formulation types span tablets, capsules, liquids, suspensions, creams, and gels for routes including oral, ocular, intranasal, subcutaneous, and transdermal. Analytical method development and CMC/regulatory consulting are integrated as complementary services. All services are fee-for-service, with all IP generated belonging to the client.

Product and service7 records
1Formulation Development Services
CategoryCDMO Core Service
Description

Formulation development services for small molecules and peptides that turn 'badly behaved molecules' into optimized formulations for preclinical, clinical, and commercial stages, addressing solubility, permeability, stability, and release profile challenges.

2Futureproof Formulations Fast™
CategoryMethodology / Differentiated Service
Description

Award-winning proprietary formulation development approach that systematically considers the molecule's characteristics, end goal, study requirements, and species to create formulations optimized for imminent studies while enabling acceleration to clinic and commercial.

3Solubility Enhancement Solutions
CategoryFormulation Development Sub-service
Description

Techniques to increase molecule solubility including solubility-enhancing excipients, spray drying, amorphous solid dispersions, milling, nanomilling, lipid nanoparticles, and liposomes.

4Permeability Enhancement Solutions
CategoryFormulation Development Sub-service
Description

Approaches to overcome permeability issues using permeability-enhancing excipients and cell-penetrating peptides, including intranasal gels and solutions formulated for crossing the blood-brain barrier for CNS indications such as Alzheimer's or Parkinson's disease.

5Release Profile Modification
CategoryFormulation Development Sub-service
Description

Methods to extend, sustain, or modify drug release profiles using size reduction, matrix formation with polymers, particle/granule coating, and component layering.

6Analytical Method Development
CategoryAnalytical Services
Description

Development and validation of analytical methods specific to client molecules, including HPLC methods for formulation projects or as standalone analytical projects.

7CMC, Analytical and Formulation Consulting
CategoryConsulting Services
Description

CMC, analytical, and formulation development consulting services, including writing CMC sections for regulatory documents such as IMPD/IND.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announced an Integrated CMC Partnership in October 2025 to provide end-to-end Chemistry, Manufacturing and Controls (CMC) services to innovator biopharma companies. The partnership combines Sai's API development expertise, Agility's formulation development, and Centrix's drug product development and clinical manufacturing. The result is a faster, more efficient pathway from preclinical to FIH clinical trials. Agility's CEO Dr Claire Thompson described the partnership as combining complementary strengths to accelerate clients' molecules through key milestones.

2Centrix Pharma Solutions
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Centrix Pharma Solutions, a specialist CDMO focused on drug product development and clinical trial manufacturing, partnered with Agility Life Sciences and Sai Life Sciences in an Integrated CMC Partnership announced October 2025. Centrix provides drug product development and clinical manufacturing capabilities that complement Agility's formulation development expertise. The partnership aims to provide end-to-end CMC services from pre-formulation through clinical trial material manufacturing.

agilitylifesciences.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Solitek brings a new concept in solid state development services for the pharmaceutical, agrochemical, and fine chemical industries. Listed as a strategic partnership on Agility's 'Our Tribe' page to help clients get their molecules to clinic and patients as quickly as possible.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Inaphaea BioLabs is a Nottingham-based pharmaceutical services company offering cell-based assays specializing in oncology and women's health. Their aim is to improve translation of early drug discovery projects toward the clinic. Listed as a strategic partnership on Agility's 'Our Tribe' page with synergistic services.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Portugal-headquartered CDMO with deep formulation, spray drying, and particle engineering capabilities for small molecules. Comparable in the spray drying / amorphous solid dispersion / lipid nanoparticle technical domains where Agility competes.

TypeEmerging player
Description

Contract development organization offering pre-formulation, formulation, and analytical services with strong presence in China and the US. Comparable in scope of formulation services but a larger and faster-scaling emerging player.

TypeDirect peer
Description

UK-based, formulation development-focused CDMO offering pre-formulation, spray drying, and GMP manufacturing for small molecules and biologics. Closest headcount and capability analogue to Agility in the UK market.

TypeDirect peer
Description

India-headquartered CRDMO with API development, formulation, and biologics capabilities serving 300+ innovator pharma and biotech clients globally. Direct peer in the integrated CMC space and Agility's strategic partner in the October 2025 alliance.

TypeBroad incumbent
Description

Global, large-scale CDMO offering formulation development, softgel, oral and injectable manufacturing, and clinical supply services. Operates broadly across many of the same customer use cases as Agility but at much greater scale and as part of a wide portfolio.

TypeBroad incumbent
Description

European CDMO with broad solid oral, sterile, and semi-solid dosage form capabilities. Competes with Agility in formulation development and GMP manufacturing but as a much larger, full-service incumbent.

TypeDirect peer
Description

UK-headquartered CDMO providing formulation development, clinical trial manufacturing, and integrated drug substance-to-patient services. Operates in the same formulation/CMC niche and competes for similar UK/EU biotech clients.

8Centrix Pharma Solutions
TypeDirect peer
Description

UK-based specialist CDMO focused on drug product development and clinical trial manufacturing. Directly comparable in scale and service scope, and Agility's partner in the Integrated CMC Partnership.

TypeDirect peer
Description

Belgium-headquartered CDMO focused on formulation development, analytical services, and drug product manufacturing for small molecules and nanomedicines. Directly comparable in scope of formulation and CMC services.

TypeBroad incumbent
Description

Global CDMO spanning small molecules, biologics, and cell/gene therapies with extensive formulation and drug product services. Competes with Agility at the high end of the formulation market and absorbs many of the same innovator clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Agility Life Sciences

Pharmaceutical Contract Development and Manufacturing Servicesagilitylifesciences.com

Agility Life Sciences is a UK-based, founder-led formulation development CDMO that helps pharmaceutical and biotech innovators solve bioavailability, solubility, and delivery challenges for small molecules and peptides across oral, ocular, intranasal, and topical routes via fee-for-service projects.

What Agility Life Sciences does

Agility Life Sciences is a privately held, founder-led formulation development CDMO founded in 2012 and headquartered in Stapleford, Nottingham, United Kingdom. The company develops drug formulations for small molecules and peptides, addressing bioavailability, solubility, permeability, stability, and targeted delivery challenges (including blood-brain barrier crossing) for pharmaceutical and biotech innovators across routes of administration spanning oral, ocular, intranasal, topical, subcutaneous, and transdermal. Its core technology portfolio covers spray drying, amorphous solid dispersions, lipid nanoparticles, liposomes, and a range of release-profile modification techniques, delivered through a proprietary methodology branded as "Futureproof Formulations Fast™." The firm also provides analytical method development and validation (HPLC and related techniques) and CMC/regulatory consulting, including authoring CMC sections for regulatory documents.

Agility operates a pure fee-for-service, project-based revenue model: all services are billed on a per-project basis, and all intellectual property generated during an engagement is retained by the client. The company goes to market through direct enterprise sales led by its CEO, CSO, and a dedicated business development executive, supported by a heavy conference presence (BOS Basel, ON Helix, ELRIG, NLS, CPHI Milan), thought-leadership content on LinkedIn, and podcast appearances by the CEO. In October 2025, Agility entered an Integrated CMC Partnership with Sai Life Sciences (a large Indian-listed CRDMO) and Centrix Pharma Solutions to offer end-to-end drug substance, formulation, and clinical manufacturing services to innovator biopharma, materially extending its distribution and service scope without organic capex. The firm's customer base spans pharma/biotech innovators as the primary segment and nutraceutical/food supplement companies as a secondary segment. With 11-50 employees and no external funding rounds disclosed, Agility is positioned as a boutique, science-led CDMO.

Agility Life Sciences firmographics

Firmographics
Name
Agility Life Sciences
Legal name
Agility Life Sciences
Website
https://agilitylifesciences.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Agility Life Sciences is a UK-based, founder-led formulation development CDMO that helps pharmaceutical and biotech innovators solve bioavailability, solubility, and delivery challenges for small molecules and peptides across oral, ocular, intranasal, and topical routes via fee-for-service projects.
Ownership category
akta.pro rank

Agility Life Sciences industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Formulation development services
  • Contract development CDMO
  • CMC consulting services
  • Analytical method development
  • Pharmaceutical formulation

Where Agility Life Sciences is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Agility Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Fee-for-service formulation development: All formulation development services are conducted on a fee-for-service basis. All IP generated during the engagement belongs to the client. This is a project-based, service revenue model targeting preclinical through commercial development stages.
  2. Fee-for-service analytical development: Analytical method development and validation services provided as standalone projects or alongside formulation projects. Project-based pricing.
  3. CMC consulting: CMC, analytical and formulation development consulting services, including writing CMC sections for regulatory documents.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Agility Life Sciences product offering

Product offering

Core offering

Agility Life Sciences is a CDMO that turns poorly behaved small molecules and peptides into optimized pharmaceutical formulations for preclinical, clinical, and commercial stages. Services include formulation development across oral, ocular, intranasal, and topical routes; solubility and permeability enhancement; lipid nanoparticle and liposomal formulations; release profile modification; analytical method development; and CMC, analytical, and regulatory consulting.

Product overview

Agility Life Sciences is an award-winning formulation development CDMO operating as a single unified service offering called 'Futureproof Formulations Fast™'. The company transforms 'badly behaved molecules' into smart formulations for small molecules and peptides. The core service portfolio includes solubility enhancement solutions (spray drying, amorphous solid dispersions, lipid nanoparticles, liposomes), permeability enhancement (particularly for CNS/blood-brain barrier delivery), and release profile modification. Formulation types span tablets, capsules, liquids, suspensions, creams, and gels for routes including oral, ocular, intranasal, subcutaneous, and transdermal. Analytical method development and CMC/regulatory consulting are integrated as complementary services. All services are fee-for-service, with all IP generated belonging to the client.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Development Services Formulation development services for small molecules and peptides that turn 'badly behaved molecules' into optimized formulations for preclinical, clinical, and commercial stages, addressing solubility, permeability, stability, and release profile challenges.
  • Futureproof Formulations Fast™ Award-winning proprietary formulation development approach that systematically considers the molecule's characteristics, end goal, study requirements, and species to create formulations optimized for imminent studies while enabling acceleration to clinic and commercial.
  • Solubility Enhancement Solutions Techniques to increase molecule solubility including solubility-enhancing excipients, spray drying, amorphous solid dispersions, milling, nanomilling, lipid nanoparticles, and liposomes.
  • Permeability Enhancement Solutions Approaches to overcome permeability issues using permeability-enhancing excipients and cell-penetrating peptides, including intranasal gels and solutions formulated for crossing the blood-brain barrier for CNS indications such as Alzheimer's or Parkinson's disease.
  • Release Profile Modification Methods to extend, sustain, or modify drug release profiles using size reduction, matrix formation with polymers, particle/granule coating, and component layering.
  • Analytical Method Development Development and validation of analytical methods specific to client molecules, including HPLC methods for formulation projects or as standalone analytical projects.
  • CMC, Analytical and Formulation Consulting CMC, analytical, and formulation development consulting services, including writing CMC sections for regulatory documents such as IMPD/IND.

Quantifiable outcome

  • Accelerated molecule progression from preclinical to clinic and commercial

Companies that use Agility Life Sciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Agility Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Agility Life Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Sai Life SciencescoreStrategic or Co-development Partner · 8 October 2025Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announced an Integrated CMC Partnership in October 2025 to provide end-to-end Chemistry, Manufacturing and Controls (CMC) services to innovator biopharma companies. The partnership combines Sai's API development expertise, Agility's formulation development, and Centrix's drug product development and clinical manufacturing. The result is a faster, more efficient pathway from preclinical to FIH clinical trials. Agility's CEO Dr Claire Thompson described the partnership as combining complementary strengths to accelerate clients' molecules through key milestones.
  • Centrix Pharma SolutionscoreStrategic or Co-development Partner · 8 October 2025Centrix Pharma Solutions, a specialist CDMO focused on drug product development and clinical trial manufacturing, partnered with Agility Life Sciences and Sai Life Sciences in an Integrated CMC Partnership announced October 2025. Centrix provides drug product development and clinical manufacturing capabilities that complement Agility's formulation development expertise. The partnership aims to provide end-to-end CMC services from pre-formulation through clinical trial material manufacturing.
  • SolitekminorStrategic or Co-development PartnerSolitek brings a new concept in solid state development services for the pharmaceutical, agrochemical, and fine chemical industries. Listed as a strategic partnership on Agility's 'Our Tribe' page to help clients get their molecules to clinic and patients as quickly as possible.
  • Inaphaea BioLabsminorStrategic or Co-development PartnerInaphaea BioLabs is a Nottingham-based pharmaceutical services company offering cell-based assays specializing in oncology and women's health. Their aim is to improve translation of early drug discovery projects toward the clinic. Listed as a strategic partnership on Agility's 'Our Tribe' page with synergistic services.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Agility Life Sciences competitors and assessment

Company assessment

Direct peers

  • Hovione: Portugal-headquartered CDMO with deep formulation, spray drying, and particle engineering capabilities for small molecules. Comparable in the spray drying / amorphous solid dispersion / lipid nanoparticle technical domains where Agility competes.
  • Upperton Pharma Solutions: UK-based, formulation development-focused CDMO offering pre-formulation, spray drying, and GMP manufacturing for small molecules and biologics. Closest headcount and capability analogue to Agility in the UK market.
  • Sai Life Sciences: India-headquartered CRDMO with API development, formulation, and biologics capabilities serving 300+ innovator pharma and biotech clients globally. Direct peer in the integrated CMC space and Agility's strategic partner in the October 2025 alliance.
  • Quotient Sciences: UK-headquartered CDMO providing formulation development, clinical trial manufacturing, and integrated drug substance-to-patient services. Operates in the same formulation/CMC niche and competes for similar UK/EU biotech clients.
  • Centrix Pharma Solutions: UK-based specialist CDMO focused on drug product development and clinical trial manufacturing. Directly comparable in scale and service scope, and Agility's partner in the Integrated CMC Partnership.
  • Ardena: Belgium-headquartered CDMO focused on formulation development, analytical services, and drug product manufacturing for small molecules and nanomedicines. Directly comparable in scope of formulation and CMC services.

Emerging players

  • BioDuro: Contract development organization offering pre-formulation, formulation, and analytical services with strong presence in China and the US. Comparable in scope of formulation services but a larger and faster-scaling emerging player.

Broad incumbents

  • Catalent: Global, large-scale CDMO offering formulation development, softgel, oral and injectable manufacturing, and clinical supply services. Operates broadly across many of the same customer use cases as Agility but at much greater scale and as part of a wide portfolio.
  • Aenova Group: European CDMO with broad solid oral, sterile, and semi-solid dosage form capabilities. Competes with Agility in formulation development and GMP manufacturing but as a much larger, full-service incumbent.
  • Lonza: Global CDMO spanning small molecules, biologics, and cell/gene therapies with extensive formulation and drug product services. Competes with Agility at the high end of the formulation market and absorbs many of the same innovator clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Agility Life Sciences social profiles

Digital presence

Agility Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Agility Life Sciences leadership team

Management profile

Number of profiles

Profiles2 records

Agility Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Agility Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agility Life Sciences

What does Agility Life Sciences do?

Agility Life Sciences is a CDMO that turns poorly behaved small molecules and peptides into optimized pharmaceutical formulations for preclinical, clinical, and commercial stages. Services include formulation development across oral, ocular, intranasal, and topical routes; solubility and permeability enhancement; lipid nanoparticle and liposomal formulations; release profile modification; analytical method development; and CMC, analytical, and regulatory consulting.

Is Agility Life Sciences a public or private company?

Agility Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Agility Life Sciences founded?

Agility Life Sciences was founded in 2012. It employs 11 to 50 people.

Where is Agility Life Sciences based?

Agility Life Sciences is headquartered in Nottingham, United Kingdom, in the Europe region.

How does Agility Life Sciences make money?

Three revenue lines are on record. Fee-for-service formulation development is the primary driver. The others are fee-for-service analytical development and CMC consulting.

Who are Agility Life Sciences's main competitors?

Direct peers on record are Hovione, Upperton Pharma Solutions, Sai Life Sciences, Quotient Sciences, Centrix Pharma Solutions and Ardena. BioDuro is listed as an emerging player. Broad incumbents are Catalent, Aenova Group and Lonza.

Does Agility Life Sciences have an API?

No public API is recorded for Agility Life Sciences.

What industry is Agility Life Sciences in?

Agility Life Sciences's product category is Pharmaceutical Contract Development and Manufacturing Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical). Its NAICS code is 541715 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovatorsSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announced an Integrated CMC Partnership to provide end-to-end chemistry, manufacturing, and controls services for innovator biopharma companies. The collaboration combines API, formulation, and drug product development expertise to accelerate drug candidates from preclinical to first-in-human trials.SailifeSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovatorsSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announced an Integrated CMC Partnership on October 8, 2025, to provide end-to-end Chemistry, Manufacturing and Controls services for innovator biopharma companies. The collaboration combines Sai's API development expertise with Agility's formulation capabilities and Centrix's clinical manufacturing strengths to streamline drug development from preclinical studies to clinical trials. This strategic alliance aims to reduce duplication, risks, costs, and timelines for clients through unified planning and seamless coordination across the CMC value chain.GlobeNewswireSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovatorsSai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announced an integrated CMC partnership to provide end-to-end chemistry, manufacturing, and controls services for innovator biopharma companies. The collaboration combines API, formulation, and drug product development expertise to accelerate drug candidates from preclinical to first-in-human trials.Stock TitanConduit Pharma Partners with Agility Life Sciences to Advance Autoimmune Drug FormulationsConduit Pharmaceuticals entered a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage forms for its autoimmune pipeline. The collaboration aims to create enhanced formulations for future clinical trials, leveraging Conduit's proprietary composition-of-matter IP. The company plans to advance Phase 2 trials using existing data packages.GlobeNewswireConduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune PipelineConduit Pharmaceuticals announced a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage forms for its autoimmune pipeline assets. The collaboration aims to create enhanced formulations under composition-of-matter IP, supporting future Phase 2 trials and licensing opportunities.